<DOC>
	<DOCNO>NCT00573833</DOCNO>
	<brief_summary>RATIONALE : Internal radiation therapy use radioactive material place directly near tumor kill tumor cell . PURPOSE : This clinical trial study side effect well internal radiation therapy work treat patient prostate cancer .</brief_summary>
	<brief_title>Internal Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To assess feasibility high-dose rate ( HDR ) brachytherapy ( without use external-beam radiotherapy ) definitive treatment patient intermediate-risk prostate cancer . - To assess acceptable toxicity , define treatment related toxicity ( urinary rectal ) , bad see patient treated conventional therapy ( grade 3 urinary toxicity &lt; 10 % grade 3 rectal toxicity &lt; 10 % ) . Secondary - To achieve adequate dosimetric coverage prostate comparable current standard . - To assess effect treatment sexual function . OUTLINE : Patients undergo 4 high-dose rate brachytherapy treatment 2 day . Patients complete bladder , bowel , sexual function , quality life questionnaire , include International Index Erectile Function ( IIEF ) questionnaire , International Prostate Symptom Score Index ( IPSS ) , MSKCC Prostate Quality Life questionnaire baseline every follow-up visit . After completion study treatment , patient follow every 3 month 1 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Intermediaterisk adenocarcinoma prostate , define 1of follow criterion : PSA 1020 ng/mL Gleason score ≥ 7 Stage ≥ T2b AND &lt; T3 Less 20 % risk seminal vesicle involvement lymph node involve base upon Kattan nomogram ( pretreatment risk IMRT ) Prostate size &lt; 60 cc MRI CT image International Prostate Symptom Score Index ≤ 15 Exclusion criterion : Evidence definitive extracapsular extension/seminal vesicle invasion pelvic adenopathy MRI ( endorectal coil ) DRE ( digital rectal examination ) Suspected extracapsular disease consider exclusion criterion PSA &gt; 20 ng/mL Presence distant metastases PATIENT CHARACTERISTICS : WBC ≥ 3,500/mm³ Platelet count ≥ 75,000/mm³ Hemoglobin ≥ 10 g/dL Creatinine ≤ 1.5 mg/dL Liver function test ≤ 1.5 time normal INR ≤ 2.5 Able complete quality life questionnaire Able give inform consent No active perineal infection No history urethral stricture No prior history pelvic malignancy No prior history lymphoma disease , ulcerative colitis , anal fissure No contraindication general anesthesia No pacemaker PRIOR CONCURRENT THERAPY : No prior transurethral resection prostate No prior pelvic radiotherapy No prior treatment prostate cancer except hormone therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
</DOC>